Science 24 January 1992: Vol. 255. no. 5043, pp. 459 - 462 DOI: 10.1126/science.1346476

Prev | Table of Contents | Next

Articles

A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging.

L. Gu, W. M. Tsark, D. A. Brown, S. Blanchard, T. W. Synold, and S. E. Kane (2009)
PNAS 106, 5394-5399
 |  Abstract »  |  Full Text »  |  PDF »

Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif.

S. Ye, D. P. MacEachran, J. W. Hamilton, G. A. O'Toole, and B. A. Stanton (2008)
Am J Physiol Cell Physiol 295, C807-C818
 |  Abstract »  |  Full Text »  |  PDF »

Involvement of MDR1 Function in Proliferation of Tumour Cells.

S.-Y. Katoh, M. Ueno, and N. Takakura (2008)
J. Biochem. 143, 517-524
 |  Abstract »  |  Full Text »  |  PDF »

Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System..

B. Sarkadi, L. Homolya, G. Szakacs, and A. Varadi (2006)
Physiol Rev 86, 1179-1236
 |  Abstract »  |  Full Text »  |  PDF »

Tumor-Derived p53 Mutants Induce NF-{kappa}B2 Gene Expression.

M. J. Scian, K. E. R. Stagliano, M. A. E. Anderson, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb (2005)
Mol. Cell. Biol. 25, 10097-10110
 |  Abstract »  |  Full Text »  |  PDF »

The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma.

W.-C. Yen and W. W. Lamph (2005)
Mol. Cancer Ther. 4, 824-834
 |  Abstract »  |  Full Text »  |  PDF »

Differential Regulation of MDR1 Transcription by the p53 Family Members: ROLE OF THE DNA BINDING DOMAIN.

R. A. Johnson, E. M. Shepard, and K. W. Scotto (2005)
J. Biol. Chem. 280, 13213-13219
 |  Abstract »  |  Full Text »  |  PDF »

A Selective Retinoid X Receptor Agonist Bexarotene (Targretin) Prevents and Overcomes Acquired Paclitaxel (Taxol) Resistance in Human Non-Small Cell Lung Cancer.

W.-C. Yen, M. R. Corpuz, R. Y. Prudente, T. A. Cooke, R. P. Bissonnette, A. Negro-Vilar, and W. W. Lamph (2004)
Clin. Cancer Res. 10, 8656-8664
 |  Abstract »  |  Full Text »  |  PDF »

The role of nuclear Y-box binding protein 1 as a global marker in drug resistance.

M. Kuwano, Y. Oda, H. Izumi, S.-J. Yang, T. Uchiumi, Y. Iwamoto, M. Toi, T. Fujii, H. Yamana, H. Kinoshita, et al. (2004)
Mol. Cancer Ther. 3, 1485-1492
 |  Abstract »  |  Full Text »  |  PDF »

Modulation of Gene Expression by Tumor-Derived p53 Mutants.

M. J. Scian, K. E. R. Stagliano, M. A. Ellis, S. Hassan, M. Bowman, M. F. Miles, S. P. Deb, and S. Deb (2004)
Cancer Res. 64, 7447-7454
 |  Abstract »  |  Full Text »  |  PDF »

Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies.

D. Mahadevan and A. F. List (2004)
Blood 104, 1940-1951
 |  Abstract »  |  Full Text »  |  PDF »

The Y-box-binding Protein, YB1, Is a Potential Negative Regulator of the p53 Tumor Suppressor.

A. Lasham, S. Moloney, T. Hale, C. Homer, Y. F. Zhang, J. G. Murison, A. W. Braithwaite, and J. Watson (2003)
J. Biol. Chem. 278, 35516-35523
 |  Abstract »  |  Full Text »  |  PDF »

Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease?.

G-T Ho, F M Moodie, and J Satsangi (2003)
Gut 52, 759-766
 |  Abstract »  |  Full Text »

p53 facilitates degradation of human T-cell leukaemia virus type I Tax-binding protein through a proteasome-dependent pathway.

I. H. Chowdhury, M. Radonovich, R. Mahieux, C. Pise-Masison, S. Muralidhar, and J. N. Brady (2003)
J. Gen. Virol. 84, 897-906
 |  Abstract »  |  Full Text »  |  PDF »

Nuclear Factor-Y Binding to the Topoisomerase IIalpha Promoter Is Inhibited by Both the p53 Tumor Suppressor and Anticancer Drugs.

A. A. Joshi, Z. Wu, R. F. Reed, and D. P. Suttle (2003)
Mol. Pharmacol. 63, 359-367
 |  Abstract »  |  Full Text »  |  PDF »

Cross-Regulation of T Cell Growth Factor Expression by p53 and the Tax Oncogene.

S. Chaudhry, W. J. Freebern, J. L. Smith, W. G. Butscher, C. M. Haggerty, and K. Gardner (2002)
J. Immunol. 169, 6767-6778
 |  Abstract »  |  Full Text »  |  PDF »

Regulation of the Mdr1 isoforms in a p53-deficient mouse model.

J. A. Bush and G. Li (2002)
Carcinogenesis 23, 1603-1607
 |  Abstract »  |  Full Text »  |  PDF »

MDR1 Gene Polymorphisms Affect Therapy Outcome in Acute Myeloid Leukemia Patients.

T. Illmer, U. S. Schuler, C. Thiede, U. I. Schwarz, R. B. Kim, S. Gotthard, D. Freund, U. Schakel, G. Ehninger, and M. Schaich (2002)
Cancer Res. 62, 4955-4962
 |  Abstract »  |  Full Text »  |  PDF »

Identification and Characterization of HIPK2 Interacting with p73 and Modulating Functions of the p53 Family in Vivo.

E.-J. Kim, J.-S. Park, and S.-J. Um (2002)
J. Biol. Chem. 277, 32020-32028
 |  Abstract »  |  Full Text »  |  PDF »

Activation of Phospholipase C Induces the Expression of the Multidrug Resistance (MDR1) Gene through the Raf-MAPK Pathway.

J.-M. Yang, A. D. Vassil, and W. N. Hait (2001)
Mol. Pharmacol. 60, 674-680
 |  Abstract »  |  Full Text »  |  PDF »

Transcription of MDR1: A Therapeutic Target.

K. W. Scotto and R. A. Johnson (2001)
Mol. Interv. 1, 117-125
 |  Abstract »  |  Full Text »  |  PDF »

Effect of ultraviolet light, methyl methanesulfonate and ionizing radiation on the genotoxic response and apoptosis of mouse fibroblasts lacking c-Fos, p53 or both.

D. Lackinger, U. Eichhorn, and B. Kaina (2001)
Mutagenesis 16, 233-241
 |  Abstract »  |  Full Text »  |  PDF »

Increased Resistance to Anticancer Therapy of Mouse Cells Lacking the Poly(ADP-ribose) Polymerase Attributable to Up-Regulation of the Multidrug Resistance Gene Product P-Glycoprotein.

G. Wurzer, Z. Herceg, and J. Wsierska-Gadek (2000)
Cancer Res. 60, 4238-4244
 |  Abstract »  |  Full Text »

MDR1 Gene Expression and Outcome in Osteosarcoma: A Prospective, Multicenter Study.

J. S. Wunder, S. B. Bull, V. Aneliunas, P. D. Lee, A. M. Davis, C. P. Beauchamp, E. U. Conrad, R. J. Grimer, J. H. Healey, M. J. Rock, et al. (2000)
J. Clin. Oncol. 18, 2685-2694
 |  Abstract »  |  Full Text »  |  PDF »

Cyclic AMP and Fluconazole Resistance in Saccharomyces cerevisiae.

D. P. Kontoyiannis and S. Rupp (2000)
Antimicrob. Agents Chemother. 44, 1743-1744
 |  Abstract »  |  Full Text »

Wild Type and Mutant p53 Differentially Regulate the Gene Expression of Human Collagenase-3 (hMMP-13).

Y. Sun, J. M. Cheung, J. Martel-Pelletier, J. P. Pelletier, L. Wenger, R. D. Altman, D. S. Howell, and H. S. Cheung (2000)
J. Biol. Chem. 275, 11327-11332
 |  Abstract »  |  Full Text »  |  PDF »

Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line.

K. E. Pestell, S. M. Hobbs, J. C. Titley, L. R. Kelland, and M. I. Walton (2000)
Mol. Pharmacol. 57, 503-511
 |  Abstract »  |  Full Text »

O6-Methylguanine-DNA methyltransferase activity, p53 gene status and BCNU resistance in mouse astrocytes.

C. L. Nutt, N. A. Loktionova, A. E. Pegg, A. F. Chambers, and J.g. Cairncross (1999)
Carcinogenesis 20, 2361-2365
 |  Abstract »  |  Full Text »  |  PDF »

p53 Represses CAAT Enhancer-binding Protein (C/EBP)-dependent Transcription of the Albumin Gene. A MOLECULAR MECHANISM INVOLVED IN VIRAL LIVER INFECTION WITH IMPLICATIONS FOR HEPATOCARCINOGENESIS.

S. Kubicka, F. Kuhnel, L. Zender, K. L. Rudolph, J. Plumpe, M. Manns, and C. Trautwein (1999)
J. Biol. Chem. 274, 32137-32144
 |  Abstract »  |  Full Text »  |  PDF »

Elevated Expression of Ribosomal Protein Genes L37, RPP-1, and S2 in the Presence of Mutant p53.

W. T. Loging and D. Reisman (1999)
Cancer Epidemiol. Biomarkers Prev. 8, 1011-1016
 |  Abstract »  |  Full Text »

p53 Negatively Regulates cdc2 Transcription via the CCAAT-binding NF-Y Transcription Factor.

J. Yun, H.-D. Chae, H. E. Choy, J. Chung, H.-S. Yoo, M.-H. Han, and D. Y. Shin (1999)
J. Biol. Chem. 274, 29677-29682
 |  Abstract »  |  Full Text »  |  PDF »

Expression of the Lung Resistance Protein Predicts Poor Outcome in Patients with Multiple Myeloma.

M. Filipits, J. Drach, G. Pohl, J. Schuster, T. Stranzl, J. Ackermann, R. Konigsberg, H. Kaufmann, H. Gisslinger, H. Huber, et al. (1999)
Clin. Cancer Res. 5, 2426-2430
 |  Abstract »  |  Full Text »  |  PDF »

Clinical Significance of Apoptosis-Related Factors p53, Mdm2, and Bcl-2 in Advanced Ovarian Cancer.

M. Baekelandt, G. B. Kristensen, J. M. Nesland, C. G. Trope, and R. Holm (1999)
J. Clin. Oncol. 17, 2061
 |  Abstract »  |  Full Text »  |  PDF »

Transcriptional Activation of the Human Glutathione Peroxidase Promoter by p53.

M. Tan, S. Li, M. Swaroop, K. Guan, L. W. Oberley, and Y. Sun (1999)
J. Biol. Chem. 274, 12061-12066
 |  Abstract »  |  Full Text »  |  PDF »

Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: Evidence that 15-lipoxygenase is a mutator gene.

U. P. Kelavkar and K. F. Badr (1999)
PNAS 96, 4378-4383
 |  Abstract »  |  Full Text »  |  PDF »

p73 Function Is Inhibited by Tumor-Derived p53 Mutants in Mammalian Cells.

C. J. Di Como, C. Gaiddon, and C. Prives (1999)
Mol. Cell. Biol. 19, 1438-1449
 |  Abstract »  |  Full Text »  |  PDF »

Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing.

K. Will, G. Warnecke, L. Wiesmuller, and W. Deppert (1998)
PNAS 95, 13681-13686
 |  Abstract »  |  Full Text »  |  PDF »

Ectopic Expression of cdc2/cdc28 Kinase Subunit Homo sapiens 1 Uncouples Cyclin B Metabolism from the Mitotic Spindle Cell Cycle Checkpoint.

M. L. Hixon, A. I. Flores, M. W. Wagner, and A. Gualberto (1998)
Mol. Cell. Biol. 18, 6224-6237
 |  Abstract »  |  Full Text »

Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain.

M. W. Frazier, X. He, J. Wang, Z. Gu, J. L. Cleveland, and G. P. Zambetti (1998)
Mol. Cell. Biol. 18, 3735-3743
 |  Abstract »  |  Full Text »

Review : p53 in the pathogenesis, diagnosis, and treatment of cancer.

E. Perz and J. G. Kuhn (1998)
Journal of Oncology Pharmacy Practice 4, 75-102
 |  Abstract »  |  PDF »

The MYND Motif Is Required for Repression of Basal Transcription from the Multidrug Resistance 1 Promoter by the t(8;21) Fusion Protein.

B. Lutterbach, D. Sun, J. Schuetz, and S. W. Hiebert (1998)
Mol. Cell. Biol. 18, 3604-3611
 |  Abstract »  |  Full Text »

The p53 Tumor Suppressor Inhibits Transcription of the TATA-less Mouse DP1 Promoter.

R. V. Gopalkrishnan, E. W.-F. Lam, and C. Kedinger (1998)
J. Biol. Chem. 273, 10972-10978
 |  Abstract »  |  Full Text »  |  PDF »

Enhanced MDR1 Gene Expression in Human T-Cell Leukemia Virus-I-Infected Patients Offers New Prospects for Therapy.

A. Lau, S. Nightingale, G. P. Taylor, T. W. Gant, and A. J. Cann (1998)
Blood 91, 2467-2474
 |  Abstract »  |  Full Text »  |  PDF »

p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents.

J. V. Thottassery, G. P. Zambetti, K. Arimori, E. G. Schuetz, and J. D. Schuetz (1997)
PNAS 94, 11037-11042
 |  Abstract »  |  Full Text »  |  PDF »

Mutations of the p53 Gene as a Prognostic Factor in Aggressive B-Cell Lymphoma.

A. Ichikawa, T. Kinoshita, T. Watanabe, H. Kato, H. Nagai, K. Tsushita, H. Saito, and T. Hotta (1997)
N. Engl. J. Med. 337, 529-534
 |  Abstract »  |  Full Text »  |  PDF »

DNA Elements Recognizing NF-Y and Sp1 Regulate the Human Multidrug-Resistance Gene Promoter.

R. Sundseth, G. Macdonald, J. Ting, and A. C. King (1997)
Mol. Pharmacol. 51, 963-971
 |  Abstract »  |  Full Text »

Accumulation of Glucosylceramides in Multidrug-resistant Cancer Cells.

Y. Lavie, H.-t. Cao, S. L. Bursten, A. E. Giuliano, and M. C. Cabot (1996)
J. Biol. Chem. 271, 19530-19536
 |  Abstract »  |  Full Text »  |  PDF »

p53 Stimulates Promoter Activity of the sgk Serum/Glucocorticoid-inducible Serine/Threonine Protein Kinase Gene in Rodent Mammary Epithelial Cells.

A. C. Maiyar, A. J. Huang, P. T. Phu, H. H. Cha, and G. L. Firestone (1996)
J. Biol. Chem. 271, 12414-12422
 |  Abstract »  |  Full Text »  |  PDF »

Transcriptional Repression by the Human Homeobox Protein EVX1 in Transfected Mammalian Cells.

P. Briata, R. Van De Werken, I. Airoldi, C. Ilengo, E. Di Blas, E. Boncinelli, and G. Corte (1995)
J. Biol. Chem. 270, 27695-27701
 |  Abstract »  |  Full Text »  |  PDF »

Identification and Characterization of a Hepatoma Cell-specific Enhancer in the Mouse Multidrug Resistance mdr1b Promoter.

R. Song, M. Ikeguchi, G. Zhou, and M. T. Kuo (1995)
J. Biol. Chem. 270, 25468-25474
 |  Abstract »  |  Full Text »  |  PDF »

Modulation of Interleukin-6-induced Plasma Protein Secretion in Hepatoma Cells by p53 Species.

L. Wang, R. J. Rayanade, D. Garcia, K. Patel, H. Pan, and P. B. Sehgal (1995)
J. Biol. Chem. 270, 23159-23165
 |  Abstract »  |  Full Text »  |  PDF »

p53 and Sp1 Interact and Cooperate in the Tumor Necrosis Factor-induced Transcriptional Activation of the HIV-1 Long Terminal Repeat.

A. Gualberto and A. S. Baldwin , Jr. (1995)
J. Biol. Chem. 270, 19680-19683
 |  Abstract »  |  Full Text »  |  PDF »

Wild Type p53 Stimulates Expression from the Human Multidrug Resistance Promoter in a p53-negative Cell Line.

M. E. Goldsmith, J. M. Gudas, E. Schneider, and K. H. Cowan (1995)
J. Biol. Chem. 270, 1894-1898
 |  Abstract »  |  Full Text »  |  PDF »

Cancer Therapy Meets p53.

H. P. Rutz (1994)
N. Engl. J. Med. 331, 1314-1315
 |  Full Text »

Functions of the p53 Protein in Growth Regulation and Tumor Suppression.

J. Lin, X. Wu, J. Chen, A. Chang, and A.J. Levine (1994)
Cold Spring Harb Symp Quant Biol 59, 215-223
 |  Abstract »  |  PDF »

Expression of P-Glycoprotein in Normal and Malignant Rat Liver Cells.

C.H. Lee, G. Bradley, and V. Ling (1994)
Cold Spring Harb Symp Quant Biol 59, 607-615
 |  Abstract »  |  PDF »

Exploiting Multidrug Resistance to Treat Cancer.

M.M. Gottesman, S.V. Ambudkar, B. Ni, J.M. Aran, Y. Sugimoto, C.O. Cardarelli, and I. Pastan (1994)
Cold Spring Harb Symp Quant Biol 59, 677-683
 |  Abstract »  |  PDF »

Clinical Implications of the p53 Tumor-Suppressor Gene.

C. C. Harris and M. Hollstein (1993)
N. Engl. J. Med. 329, 1318-1327
 |  Full Text »

Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation..

X Chen, G Farmer, H Zhu, R Prywes, and C Prives (1993)
Genes & Dev. 7, 1837-1849
 |  Abstract »  |  PDF »

Regulation of the human hsp70 promoter by p53.

S. Agoff, J Hou, D. Linzer, and B Wu (1993)
Science 259, 84-87
 |  Abstract »  |  PDF »

Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53..

J Bargonetti, I Reynisdottir, P N Friedman, and C Prives (1992)
Genes & Dev. 6, 1886-1898
 |  Abstract »  |  PDF »

Repression of the insulin-like growth factor II gene by the Wilms tumor suppressor WT1.

I. Drummond, S. Madden, P Rohwer-Nutter, G. Bell, V. Sukhatme, and F. Rauscher 3rd (1992)
Science 257, 674-678
 |  Abstract »  |  PDF »

Transcriptional Repression by p53 through Direct Binding to a Novel DNA Element.

R. A. Johnson, T. A. Ince, and K. W. Scotto (2001)
J. Biol. Chem. 276, 27716-27720
 |  Abstract »  |  Full Text »  |  PDF »

Repression of Human Reduced Folate Carrier Gene Expression by Wild Type p53.

B. C. Ding, J. R. Whetstine, T. L. Witt, J. D. Schuetz, and L. H. Matherly (2001)
J. Biol. Chem. 276, 8713-8719
 |  Abstract »  |  Full Text »  |  PDF »

The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription.

J. S. Steffan, A. Kazantsev, O. Spasic-Boskovic, M. Greenwald, Y.-Z. Zhu, H. Gohler, E. E. Wanker, G. P. Bates, D. E. Housman, and L. M. Thompson (2000)
PNAS 97, 6763-6768
 |  Abstract »  |  Full Text »  |  PDF »

Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.

T. Watanabe and B. A. Sullenger (2000)
PNAS 97, 8490-8494
 |  Abstract »  |  Full Text »  |  PDF »

To Advertise   |   Find Products